Rituximab treatment for IgA vasculitis: A systematic review
ConclusionRTX seems to be a safe and useful agent in inducing disease remission and reducing previous immunosuppressive treatment in IgAV pediatric and adult patients resistant or refractory to glucocorticoids or other immunosuppressive drugs, and in those patients in whom these agents are contraindicated. Nevertheless, controlled clinical trials in are still warranted to clarify the role of RTX in IgAV.
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Clinical Trials | Databases & Libraries | Pediatrics | Rituxan | Statistics | Study | Vasculitis